FDA ends for now use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments
Posted on AllSides January 24th, 2022
From The Left
Joe Raedle/Getty Images
The Food and Drug Administration on Monday took two monoclonal antibody therapies off the list of covid-19 treatments for now, saying the medications should not be used anywhere in the United States because they are ineffective against the dominant omicron variant.
As a result, the Biden administration said it will pause distribution of the therapies, manufactured by Regeneron Pharmaceuticals and Eli Lilly, to the states.
Some content from this outlet may be limited or behind a paywall.
AllSides Media Bias Rating: Lean Left
